肿瘤细胞治疗研究
英文原题：Genetic engineering and allogeneic optimization of Vδ1 γδ CAR-T cells (ADI-270) for cancer immunotherapy.
基因工程从根本上改变了基于 T 细胞的疗法，使其具备肿瘤靶向能力、改善功能并促进同种异体应用。
基因工程从根本上改变了T细胞疗法：它使肿瘤靶向成为可能、改善细胞功能并促进异体应用。这些最初在嵌合抗原受体（CAR）T细胞中开发的策略，已逐渐成为增强其他免疫效应细胞功能的成熟范式，包括γδ T细胞。Nishimoto等人近期研究将这些工程策略应用于Vδ1 T细胞（ADI-270），使其共表达靶向CD70的CAR和显性负性TGFβRII受体（dnTGFβRII），以靶向CD70阳性恶性肿瘤，并应对免疫抑制和宿主抗移植物排斥。本评论探讨了源自T细胞、可用于γδ T细胞的工程策略，同时介绍有望推动下一代CAR-T发展的基因组编辑创新。
Genetic engineering has fundamentally transformed T cell-based therapies by enabling tumor targeting capability, improving their functionality, and facilitating allogeneic use. These strategies-originally developed in chimeric antigen receptor (CAR)-T cells-have become increasingly established as blueprints for enhancing the function of other immune effector cells, including gamma delta ( ) T cells. A recent study by Nishimoto et al showcased the adaptation of these engineering approaches to V 1 T cells (ADI-270) by coexpressing a CD70-targeted CAR and a dominant-negative TGF RII receptor (dnTGF RII) to target CD70 + malignancies, addressing immunosuppression and host-versus-graft rejection. This commentary explores T cell-derived engineering strategies applicable to T cells, while also highlighting genome-editing innovations poised to advance next-generation CAR-T development.
MEMBER ACCOUNT
登录成功会直接打开下一页。
